Experience

Davis Polk advised the underwriters in connection with the $148.5 million public offering of ordinary shares by Theravance Biopharma, Inc. Theravance Biopharma’s ordinary shares…

Davis Polk advised the sole placing agent for the placement of an aggregate of 90,000,000 ordinary shares in Hong Kong Television Network Limited for a total consideration of approximately…

Davis Polk advised the sole underwriter in connection with the initial public offering of 27,600,000 units of CITIC Capital Acquisition Corp., including 3,600,000 units purchased pursuant…

Davis Polk advised the sole placing agent for the primary placement of an aggregate of 78,000,000 new shares in Innovent Biologics, Inc. for a total consideration of approximately HK$2.4…

Davis Polk advised the joint book-running managers in connection with a $2.25 billion SEC-registered debt offering by Intel Corporation. The offering consisted of $750 million…

Davis Polk is advising an ad hoc group (the “Ad Hoc Group”) of prepetition secured term lenders and postpetition DIP term lenders in connection with American Commercial Lines Inc.’s …

Davis Polk advised the underwriters on an SEC-registered offering on Schedule B by Oesterreichische Kontrollbank Aktiengesellschaft of its $1.5 billion 1.500% guaranteed global…

Davis Polk advised the placement agent in connection with the approximately $13.5 million SEC-registered direct offering of 2,114,591 shares of common stock of Tellurian Inc. The shares are…

Davis Polk advised Afya Limited on its SEC-registered follow-on offering of an aggregate of 12,426,740 Class A common shares, of which 3,019,928 shares were issued and sold by Afya and…

Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 6,500,000 shares of common stock of Applied Genetic Technologies…